Yes, I just caught that it was in Germany.
No youāre right , itās German, its only a Danish university involved. Either way, no direct end product.
Sorry. That last link points not to the schizophrenia drug but to an epilepsy drug.
Hereās the only mention so far on their website about CBD and schizophrenia
http://www.insysrx.com/investors/recent-news/
Hereās a direct link to the news article
http://www.azbio.org/insys-therapeutics-fda-orphan-drug-designation-pediatric-schizophrenia
http://zynerba.com/in-development/
A CBD patch, probably not of much use to us, but 'psychiatric disorders ā is mentioned on the page albeit as future applications for cbd.
The reason they had tolerability issues was because og THC, not CBD, because that version of GW42003 contained both THC and CBD when they tested the effectiveness of GW42003 on Ulcerus Colites.
It is stated there that they (GW Pharma) will decrease the THC, and try again.
THC is no good for psychosis anyway, but CDB is, so it will only be a good thing if they eliminate the THC from the medicine.
They should not label the anti-psychotic medicine the same as the anti-infammatory one, THC has anti-inflammatory properties (and so has CBD), but THC has no anti-psychotic properties, so THC has nothing to do in a anti-pshycotic medicine.
has cbd ,medication stoppedā¦?
or the process is continuedā¦